Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 9:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 370 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: OVARY Clear all
Completed Not applicable Interventional

Randomized Study of Decreased Hyperinsulinemia on the Ovulatory Response to Clomiphene Citrate in Women With Polycystic Ovary Syndrome

NCT00005104
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperinsulinism
Interventions
clomiphene citrate, metformin
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
18 Years to 40 Years · Female only
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
5
States / cities
Birmingham, Alabama • Shreveport, Louisiana • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 29, 2026, 9:42 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Blood Vessel Function in Adolescents and Women With Polycystic Ovary Syndrome

NCT01615562
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS)
Interventions
Not listed
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
14 Years to 40 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Paleo Versus Healthy ADA Diets for Treatment of Polycystic Ovarian Syndrome (PCOS)

NCT02190097
View directory record Official record
Conditions
Polycystic Ovarian Syndrome
Interventions
Paleolithic diet, American Diabetes Association diet
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Heat Therapy and Cardiometabolic Health in Obese Women

NCT03644524
View directory record Official record
Conditions
Obesity, Polycystic Ovary Syndrome, Prehypertension, PreDiabetes, Cardiovascular Risk Factor, Metabolic Syndrome
Interventions
Heat therapy
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 29, 2026, 9:42 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS

NCT03905603
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
ACTH, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
20 Years to 49 Years · Female only
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 29, 2026, 9:42 AM EDT
Completed No phase listed Observational

Gynecologic Cancer Lymphedema Questionnaire as a Clinical Care Tool to Identify Lower Extremity Lymphedema

NCT00944944
View directory record Official record
Conditions
Ovarian Cancer, Uterine Cancer, Vaginal Cancer, Lymphedema
Interventions
limb volume measurements and GCLQ lymphedema symptom assessment questionnaire, GCLQ lymphedema symptom assessment questionnaire
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years and older · Female only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2010 · Synced Oct 29, 2026, 9:42 AM EDT
Completed No phase listed Observational

Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk

NCT00043472
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years to 100 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Not applicable Interventional

Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries

NCT00098800
View directory record Official record
Conditions
brca1 Mutation Carrier, brca2 Mutation Carrier, Ovarian Cancer
Interventions
fenretinide
Drug
Lead sponsor
University of Arizona
Other
Eligibility
30 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 29, 2026, 9:42 AM EDT
Terminated Phase 1Phase 2 Interventional

Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer

NCT01535157
View directory record Official record
Conditions
Ovarian Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasms, Primary Peritoneal Carcinoma
Interventions
Fenretinide/LXS + Ketoconazole
Drug
Lead sponsor
South Plains Oncology Consortium
Network
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
3
States / cities
Oklahoma City, Oklahoma • Dallas, Texas • Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Oct 29, 2026, 9:42 AM EDT
Terminated Not applicable Interventional

A Cooking and Eating Study

NCT01079845
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Nutrition Education, Dietary Counseling, and Cooking
Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
13 Years to 21 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Oct 29, 2026, 9:42 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

FHA: Characterization of Metabolic Status, Brain Circuitry, and Stress-Reactivity

NCT00453219
View directory record Official record
Conditions
Anovulation, FHA, Eumenorrhea, Polycystic Ovary Syndrome
Interventions
Screening evaluation, Meal Response, Blood Collection, Functional MRI, Endocrine Assessment
Procedure · Genetic
Lead sponsor
Emory University
Other
Eligibility
18 Years to 35 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Not applicable Interventional Results available

Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone

NCT01427595
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Hyperandrogenism
Interventions
Metformin, Progesterone, estrace
Drug
Lead sponsor
University of Virginia
Other
Eligibility
10 Years to 17 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Phase 1 Interventional

Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers

NCT03748186
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Carcinoma, Ovary Cancer, Endometrial Cancer, Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
STRO-002
Drug
Lead sponsor
Sutro Biopharma, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 29, 2026, 9:42 AM EDT
Withdrawn Early Phase 1 Interventional

Effect of Longer-term Adrenal Suppression Using Low Dose Hydrocortisone on Androgen Overproduction

NCT01422733
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone, dexamethasone, Cosyntropin, rhCG
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 16 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Phase 2 Interventional Results available

Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer

NCT03602586
View directory record Official record
Conditions
Malignant Ovarian Clear Cell Tumor, Recurrent Ovarian Carcinoma
Interventions
Epacadostat, Pembrolizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
351
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Little Rock, Arkansas + 209 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 29, 2026, 9:42 AM EDT
Terminated Phase 1Phase 2 Interventional

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

NCT05001282
View directory record Official record
Conditions
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer, Ovary Cancer, Ovary Neoplasm, Ovary Disease, Ovary Metastasis, Ovarian Diseases, Ovarian Cancer Stage, Ovarian Epithelial Cancer, Ovarian Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Neoplasm Epithelial, Ovarian Cancer Recurrent, Endometrial Diseases, Endometrial Adenocarcinoma, Endometrial Carcinosarcoma, Endometrial Clear Cell Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Neoplasms, Endometrial Cancer Recurrent, Endometrioid Tumor, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
ELU001
Drug
Lead sponsor
Elucida Oncology
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Fullerton, California • Jacksonville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 29, 2026, 9:42 AM EDT
Recruiting Phase 1 Interventional

Bicalutamide Therapy in Young Women With NAFLD and PCOS

NCT05979389
View directory record Official record
Conditions
NAFLD, PCOS
Interventions
Bicalutamide 50 mg, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of Ovarian Morphology and Function in Overweight Women During Weight Loss

NCT01785719
View directory record Official record
Conditions
Weight Loss, Anovulation, Amenorrhea, Infertility
Interventions
Commercial Weight Loss Program
Behavioral
Lead sponsor
Cornell University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2023
U.S. locations
1
States / cities
Ithaca, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Early Phase 1 Interventional

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

NCT04041128
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Lynparza
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 29, 2026, 9:42 AM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Androgen Blockade and Progesterone Augmentation of Gonadotropin Secretion

NCT04597099
View directory record Official record
Conditions
PCOS, Polycystic Ovary Syndrome
Interventions
Micronized progesterone, Placebo, Flutamide, Estradiol patch
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Oct 29, 2026, 9:42 AM EDT
Recruiting Phase 2 Interventional

Combined Oral Contraceptive Pill and Resistance Starch

NCT06852365
View directory record Official record
Conditions
Metabolic Syndrome, Polycystic Ovary Syndrome
Interventions
wheat dextrin, Oral Contraceptives, Low-Dose, Maltodextrin
Dietary Supplement · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Phase 1 Interventional Results available

A Trial Evaluating TG4050 in Ovarian Carcinoma.

NCT03839524
View directory record Official record
Conditions
Ovarian Carcinoma, Fallopian Tube Cancer, Peritoneal Carcinoma
Interventions
TG4050
Drug
Lead sponsor
Transgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 29, 2026, 9:42 AM EDT
Not listed Phase 1Phase 2 Interventional

ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors

NCT04205227
View directory record Official record
Conditions
Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
Interventions
ENB003, Pembrolizumab
Drug
Lead sponsor
ENB Therapeutics, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 29, 2026, 9:42 AM EDT
Completed Not applicable Interventional

The RECHARGE Low Carbohydrate Diet Trial for Metastatic Cancer

NCT00444054
View directory record Official record
Conditions
Cancer, Breast Cancer, Colon Cancer, Cervical Cancer, Uterine Cancer, Ovarian Cancer
Interventions
Very low carbohydrate diet (approximately 20 grams per day)
Behavioral
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 29, 2026, 9:42 AM EDT